newsfilter
← Latest News
GlobeNewswire·

Allogene Therapeutics Reports Second Quarter 2026 Financial Results and Business Update

ALLO
  • The Phase 2 ALPHA3 trial for cemacabtagene ansegedleucel (Cema-Cel) in first-line large B-cell lymphoma showed 58.3% MRD negativity in the treatment arm versus 16.7% in the observation arm, leading to FDA RMAT & Fast Track designations.
  • Cema-Cel demonstrated a favorable safety profile with no treatment-related serious adverse events, no CRS or ICANS, no hospitalizations, & no need for tocilizumab or steroids.
  • Approximately 100 clinical sites are expected to be active by year-end 2026, exceeding the 80-site goal by six months to support enrollment.
  • ALPHA3 enrollment is projected to complete by year-end 2027, with the next interim event-free survival update anticipated in mid-2027.
  • The Phase 1 RESOLUTION trial for ALLO-329 in autoimmune disease continues brisk enrollment across dose escalation & lymphodepletion optimization cohorts.
  • Clinical data for the ALLO-329 RESOLUTION trial is expected in Q4 2026.
  • Allogene reported a net loss of $42.7 million ($0.13 per share) for Q2 2026, with total operating expenses of $51.6 million.
  • The company held $423.6 million in cash, cash equivalents, & investments as of June 30, 2026, projecting a cash runway into 2029.
  • Full-year 2026 operating expenses are guided at approximately $165 million ($225 million GAAP), excluding potential business development impacts.
  • A conference call & webcast to discuss financial results & business updates was scheduled for August 12, 2026.